In our attempt to identify biomarkers for the early detection of CRC and the plausible usage of the TP53 family members to this aim, we have recently described a significant difference in the seroreactivity for ΔNp73 between CRC patients and subjects with PL versus healthy controls [35]. This evidence concerns the gene TP53 and colorectal carcinoma.